|
| 38050155 | Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database. | J Nucl Med | 2024 |
| 36494221 | Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. | Eur Urol | 2023 |
| 37956143 | Disease mapping: Geographic differences in population rates of interventional treatment for prostate cancer in Australia. | PLoS One | 2023 |
| 37969779 | <sup>68</sup>Ga-PSMA-PET/CT in addition to mpMRI in men undergoing biopsy during active surveillance for low- to intermediate-risk prostate cancer: study protocol for a prospective cross-sectional study. | Transl Androl Urol | 2023 |
| 37258371 | Trends and variation in prostate cancer diagnosis via transperineal biopsy in Australia and New Zealand. | Urol Oncol | 2023 |
| 37190993 | Can <sup>68</sup> Ga-PSMA positron emission tomography and multiparametric MRI guide treatment for biochemical recurrence after radical prostatectomy? | BJU Int | 2023 |
| 36990608 | Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. | Lancet Oncol | 2023 |
| 37441340 | A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy. | Eur Urol Open Sci | 2023 |
| 37303121 | Treatment de-intensification for low-risk biochemical recurrence after radical prostatectomy: rational or risky? | BJU Int | 2023 |
| 37099558 | Decade-long trends in prostate cancer biopsy grade groups and treatment within a population-based registry. | BJU Int | 2023 |
| 37003085 | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. | Eur J Cancer | 2023 |
| 36746729 | Is There an Impact of Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsy on the Risk of Upgrading in Final Pathology in Prostate Cancer Patients Undergoing Radical Prostatectomy? An European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi-institutional Study. | Eur Urol Focus | 2023 |
| 36437157 | Variation in patient reported outcomes following radical prostatectomy: A bi-national registry-based study. | Urol Oncol | 2023 |
| 36577611 | Quality Indicators in the Clinical Specialty of Urology: A Systematic Review. | Eur Urol Focus | 2023 |
| 36872095 | Major changes with reduced harms in prostate cancer diagnosis and management. | Aust J Gen Pract | 2023 |
| 36710133 | Best Current Practice and Research Priorities in Active Surveillance for Prostate Cancer-A Report of a Movember International Consensus Meeting. | Eur Urol Oncol | 2023 |
| 34273231 | 'Pain-free TRUS B': a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501). | BJU Int | 2022 |
| 35440417 | Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. | Eur Urol | 2022 |
| 35450732 | Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. | Eur Urol | 2022 |
| 36167774 | A decade of declining prostatectomy margin positivity within a prostate cancer clinical quality registry. | Urol Oncol | 2022 |
| 36353657 | Estetrol Prevents Hot Flushes and Improves Quality of Life in Patients with Advanced Prostate Cancer Treated with Androgen Deprivation Therapy: The PCombi Study. | Eur Urol Open Sci | 2022 |
| 36082555 | The Detection of Prostate Cancer with Magnetic Resonance Imaging-Targeted Prostate Biopsies is Superior with the Transperineal vs the Transrectal Approach. A European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi-Institutional Study. | J Urol | 2022 |
| 36183329 | Modern paradigms for prostate cancer detection and management. | Med J Aust | 2022 |
| 33741337 | Combined Utility of <sup>68</sup>Ga-Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Predicting Prostate Biopsy Pathology. | Eur Urol Oncol | 2022 |
| 34978202 | How Does Age Affect Urinary Continence following Robot-Assisted Radical Prostatectomy? A Prospective Multi-Institutional Study Using Independently Collected, Validated Questionnaires. | J Urol | 2022 |
| 35110307 | Evaluating a multicomponent survivorship programme for men with prostate cancer in Australia: a single cohort study. | BMJ Open | 2022 |
| 35024633 | Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. | Eur Urol Open Sci | 2022 |
| 34928708 | Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP. | J Clin Oncol | 2022 |
| 34784097 | Neuroendocrine cells in prostate cancer correlate with poor outcomes: a systematic review and meta-analysis. | BJU Int | 2022 |
| 34546815 | <sup>68</sup>Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography Maximum Standardized Uptake Value as a Predictor of Gleason Pattern 4 and Pathological Upgrading in Intermediate-Risk Prostate Cancer. | J Urol | 2022 |
| 34623735 | Self-reported lack of energy or feeling depressed 12Â months after treatment in men diagnosed with prostate cancer within a population-based registry. | Psychooncology | 2022 |
| 32627306 | Prostate cancer survivorship essentials framework: guidelines for practitioners. | BJU Int | 2021 |
| 33656269 | Proposed delay for safe surgery after COVID-19. | ANZ J Surg | 2021 |
| 33653757 | High-dose vitamin D supplementation to prevent prostate cancer progression in localised cases with low-to-intermediate risk of progression on active surveillance (ProsD): protocol of a phase II randomised controlled trial. | BMJ Open | 2021 |
| 33737570 | Oxytocin receptor antagonists as a novel pharmacological agent for reducing smooth muscle tone in the human prostate. | Sci Rep | 2021 |
| 33678516 | Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival. | Eur J Cancer | 2021 |
| 33617330 | Risk-Based Selection for Active Surveillance: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Initiative. | J Urol | 2021 |
| 33504356 | Correction to: Navigate: a study protocol for a randomised controlled trial of an online treatment decision aid for men with low-risk prostate cancer and their partners. | Trials | 2021 |
| 33634949 | Utilization of telehealth by surgeons during the COVID 19 pandemic in Australia: lessons learnt. | ANZ J Surg | 2021 |
| 33660442 | Predictors of erectile dysfunction after transperineal template prostate biopsy. | Investig Clin Urol | 2021 |
| 34766688 | Telehealth in surgery: an umbrella review. | ANZ J Surg | 2021 |
| 34729965 | Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer? | Investig Clin Urol | 2021 |
| 34413304 | The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. | Nat Commun | 2021 |
| 34076753 | <sup>68</sup>Ga-PSMA-PET screening and transponder-guided salvage radiotherapy to the prostate bed alone for biochemical recurrence following prostatectomy: interim outcomes of a phase II trial. | World J Urol | 2021 |
| 34152673 | Patient perceptions of surgical telehealth consultations during the COVID 19 pandemic in Australia: Lessons for future implementation. | ANZ J Surg | 2021 |
| 33984175 | An integrated multicomponent care model for men affected by prostate cancer: A feasibility study of TrueNTH Australia. | Psychooncology | 2021 |
| 33977631 | Patterns of care for prostate cancer treatment and improving outcomes - are national registries the answer? | BJU Int | 2021 |
| 34030924 | Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. | Eur Urol | 2021 |
| 34111999 | High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids. | SLAS Discov | 2021 |
| 33341285 | Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial. | Eur Urol | 2021 |